Acro Biomedical (ACBM) Non Operating Interest Expenses (2018 - 2025)

Acro Biomedical has reported Non Operating Interest Expenses for 8 years, with the latest figure at $2710.0 in Q3 2025.

• On a quarterly basis, Non Operating Interest Expenses rose 141.32% year-over-year to $2710.0 in Q3 2025; TTM through Sep 2025 was $7230.0, a 81.98% increase from a year earlier, with the FY2024 full-year figure at $4339.0, up 35.34% from the prior year.
• Non Operating Interest Expenses was $2710.0 for Q3 2025 at Acro Biomedical, up from $1948.0 in the prior quarter.
• The five-year high for Non Operating Interest Expenses was $2710.0 in Q3 2025, with the low at $178.0 in Q3 2021.
• Average Non Operating Interest Expenses over 5 years is $1027.7, with a median of $839.0 recorded in 2023.
• The sharpest annual moves came in 2021 and 2022: Non Operating Interest Expenses soared 467.57% in 2021, then tumbled 91.65% in 2022.
• Over 5 years, Non Operating Interest Expenses stood at $202.0 in 2021, then jumped by 289.6% to $787.0 in 2022, then gained by 6.61% to $839.0 in 2023, then jumped by 43.62% to $1205.0 in 2024, then surged by 124.9% to $2710.0 in 2025.
• The last three Non Operating Interest Expenses figures came in at $2710.0 (Q3 2025), $1948.0 (Q2 2025), and $1367.0 (Q1 2025), per Business Quant data.